What is the interpretation of the provided bone density report and the recommended management for this patient with osteopenia and moderate fracture risk?

Bone Density Report Interpretation: Osteopenia with Moderate Fracture Risk

This patient has osteopenia (volumetric spine BMD 91.6 mg/cm³ and hip T-scores between -1.0 and -2.5) and requires immediate FRAX calculation to determine whether pharmacologic therapy is indicated. 1

Understanding Your Results

Your bone density measurements show:

• Lumbar spine volumetric BMD: 91.6 mg/cm³ (osteopenia range: 80-120 mg/cm³) 2
• Femoral neck T-score: -1.45 (osteopenia range: -1.0 to -2.5) 2
• Total hip T-score: -1.75 (osteopenia range: -1.0 to -2.5) 2

The lowest T-score (-1.75 at total hip) determines your diagnostic category of osteopenia. 2 The report notes "moderate fracture risk," but this designation alone does not determine treatment—you need a formal FRAX calculation. 1, 3

Immediate Next Steps: Calculate Your 10-Year Fracture Risk

You must have a FRAX score calculated using your femoral neck BMD plus clinical risk factors (age, weight, height, smoking status, alcohol use, family history of hip fracture, prior fracture history, glucocorticoid use, rheumatoid arthritis, and secondary osteoporosis causes). 2, 1 This calculation is mandatory because osteopenia diagnosis alone does not indicate treatment. 3

Treatment Thresholds Based on FRAX

Pharmacologic therapy with bisphosphonates is indicated if: 2, 1, 3

• 10-year risk of major osteoporotic fracture ≥20%, OR
• 10-year risk of hip fracture ≥3%, OR
• You have a history of fragility fracture after age 50 (this triggers immediate treatment regardless of FRAX score) 1, 3

If your FRAX scores are below these thresholds, defer pharmacologic therapy and repeat DXA in 1-2 years. 2, 1

Universal Lifestyle Interventions (Required for All Patients)

Regardless of whether you start medication, you must implement these measures immediately: 2, 1, 3

• Calcium supplementation: 1,000-1,200 mg daily (from diet plus supplements) 2, 1, 3
• Vitamin D supplementation: 800-1,000 IU daily, targeting serum 25-hydroxyvitamin D ≥20 ng/mL 2, 1, 3
• Weight-bearing exercise: ≥30 minutes, ≥3 days per week (walking, jogging, resistance training) 1, 3
• Smoking cessation (tobacco accelerates bone loss) 2, 1, 3
• Limit alcohol to ≤1-2 standard drinks per day 2, 1, 3
• Fall prevention strategies (home safety assessment, balance training) 1, 3

If Pharmacologic Therapy Is Indicated

Oral bisphosphonates are the mandatory first-line treatment, with alendronate 70 mg once weekly or risedronate 35 mg once weekly as preferred options. 1, 3 High-certainty evidence shows bisphosphonates reduce hip fractures by 50% and vertebral fractures by 47-56% over 3 years. 3

Critical Administration Requirements for Oral Bisphosphonates

• Take on an empty stomach with a full glass of water, 30-60 minutes before any food or other medications 4
• Remain upright (standing or sitting) for at least 30 minutes after taking the medication 4
• Separate calcium and vitamin D supplements by at least 30 minutes from bisphosphonate dosing (calcium inactivates bisphosphonates) 4

Treatment Duration and Monitoring

• Initial treatment duration is 5 years, after which fracture risk should be reassessed 1, 3
• Do not monitor bone density during the initial 5-year treatment period—bisphosphonates reduce fractures even when BMD does not increase 3
• After 5 years, reassess FRAX to determine whether to continue, pause, or switch therapy 3

Contraindications to Oral Bisphosphonates

Oral bisphosphonates are contraindicated if you have: 4

• Kidney function with eGFR <35 mL/min/1.73 m²
• Esophageal abnormalities that delay emptying
• Inability to remain upright for 30 minutes after dosing
• Uncorrected hypocalcemia

If you cannot tolerate oral bisphosphonates, denosumab 60 mg subcutaneously every 6 months is the recommended alternative. 1, 3 However, denosumab must never be stopped abruptly without transitioning to bisphosphonate therapy due to risk of multiple vertebral fractures. 1, 3

Addressing Incidental Findings

Your report notes several incidental findings that require clinical correlation:

• Degenerative changes in spine, SI joints, and hips: These may artificially elevate lumbar spine BMD measurements, potentially masking true bone loss 1
• Aortic vascular calcification: Correlate with cardiovascular risk assessment
• Possible left renal calculus: Correlate with any prior kidney imaging or symptoms
• Colonic diverticulosis: Routine finding requiring no specific action unless symptomatic

Screening for Secondary Causes of Bone Loss

All patients with osteopenia require evaluation for reversible secondary causes: 1, 3

• Vitamin D deficiency (check serum 25-hydroxyvitamin D)
• Hyperparathyroidism (check serum calcium, phosphorus, PTH, alkaline phosphatase)
• Hyperthyroidism
• Hypogonadism/estrogen deficiency
• Chronic glucocorticoid exposure (≥5 mg prednisone daily for ≥3 months)
• Malabsorption disorders
• Excessive alcohol use

Common Pitfalls to Avoid

• Do not start bisphosphonates without first correcting vitamin D deficiency and ensuring adequate calcium intake—this reduces treatment efficacy 4
• Do not use T-scores alone to make treatment decisions—comprehensive fracture risk assessment with FRAX is mandatory 1, 3
• Do not assume "moderate fracture risk" on the report means you need medication—formal FRAX calculation determines treatment 1, 3
• If you start denosumab, never discontinue it without transitioning to another antiresorptive agent 1, 3

Monitoring Schedule

If you do NOT start medication (FRAX below treatment thresholds): 2, 1

• Repeat DXA in 1-2 years
• Continue calcium, vitamin D, and lifestyle measures
• Reassess FRAX at each DXA

If you DO start medication: 3

• No routine DXA monitoring for the first 5 years
• Continue calcium and vitamin D supplementation throughout treatment
• Reassess fracture risk after 5 years to determine continuation